GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vicadrostat   Click here for help

GtoPdb Ligand ID: 13885

Synonyms: compound 29 A [WO2016014736A1]
Compound class: Synthetic organic
Comment: Vicadrostat (BI 690517) is an orally bioavailable aldosterone synthase (CYP11B2) inhibitor [2]. Reducing aldosterone biosynthesis is proposed as an alternative to mineralocorticoid receptor antagonist therapy for the management of treatment-resistant hypertension (with aldosterone excess) [3-4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 85.92
Molecular weight 317.73
XLogP 1.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@@]1(CC2=C(C(=O)O1)N(C=N2)C3=CC=C(C#N)C(=C3)Cl)CO
Isomeric SMILES C[C@@]1(CC2=C(C(=O)O1)N(C=N2)C3=CC(=C(C=C3)C#N)Cl)CO
InChI InChI=1S/C15H12ClN3O3/c1-15(7-20)5-12-13(14(21)22-15)19(8-18-12)10-3-2-9(6-17)11(16)4-10/h2-4,8,20H,5,7H2,1H3/t15-/m1/s1
InChI Key MCVIVPZYYMNCAW-OAHLLOKOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. (2024)
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Diabetes Obes Metab, 26 (6): 2128-2138. [PMID:38497241]
2. Burke J, Cogan D, Lord J, Marshall DR, McBikken BP, Yu M, Zhang Y, Cerny MA, Fader L, Frederick KS et al.. (2016)
Aldosterone synthase inhibitors.
Patent number: WO2016014736A1. Assignee: Boehringer Ingelheim International Gmbh. Priority date: 23/07/2015. Publication date: 28/01/2016.
3. Feldman JM, Frishman WH, Aronow WS. (2024)
Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
Cardiol Rev, [Epub ahead of print]. [PMID:38358268]
4. Helmeczi W, Hundemer GL. (2025)
Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors.
Curr Opin Nephrol Hypertens, 34 (3): 241-246. [PMID:40012539]
5. Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R et al.. (2024)
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Nephrol Dial Transplant, [Epub ahead of print]. [PMID:39533115]